Tanaka E - Search Results

1

Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.

Suzuki T, Tanaka E, Matsumoto A, Urushihara A, Sodeyama T. Suzuki T, et al. Among authors: tanaka e. J Med Virol. 1995 Jun;46(2):162-8. doi: 10.1002/jmv.1890460215. J Med Virol. 1995. PMID: 7636506

2

Serum collagen type IV for the assessment of fibrosis and resistance to interferon therapy in chronic hepatitis C.

Yabu K, Kiyosawa K, Mori H, Matsumoto A, Yoshizawa K, Tanaka E, Furuta S. Yabu K, et al. Among authors: tanaka e. Scand J Gastroenterol. 1994 May;29(5):474-9. doi: 10.3109/00365529409096841. Scand J Gastroenterol. 1994. PMID: 7518613

3

Changes in antibody titers to hepatitis C virus following interferon therapy for chronic infection.

Urushihara A, Sodeyama T, Matsumoto A, Tanaka E. Urushihara A, et al. Among authors: tanaka e. J Med Virol. 1994 Apr;42(4):348-56. doi: 10.1002/jmv.1890420405. J Med Virol. 1994. PMID: 7519250

4

Natural history of hepatitis C.

Kiyosawa K, Tanaka E, Sodeyama T, Furuta S. Kiyosawa K, et al. Among authors: tanaka e. Intervirology. 1994;37(2):101-7. doi: 10.1159/000150363. Intervirology. 1994. PMID: 7529217 Review.

5

Detection of hepatitis C virus markers and hepatitis C virus genomic-RNA after needlestick accidents.

Sodeyama T, Kiyosawa K, Urushihara A, Matsumoto A, Tanaka E, Furuta S, Akahane Y. Sodeyama T, et al. Among authors: tanaka e. Arch Intern Med. 1993 Jul 12;153(13):1565-72. Arch Intern Med. 1993. PMID: 7686741

6

Low prevalence of hepatitis C virus infection in patients with auto-immune hepatitis type 1.

Tanaka E, Kiyosawa K, Seki T, Matsumoto A, Sodeyama T, Furuta S, Kumagai T, Kohara M. Tanaka E, et al. J Gastroenterol Hepatol. 1993 Sep-Oct;8(5):442-7. doi: 10.1111/j.1440-1746.1993.tb01545.x. J Gastroenterol Hepatol. 1993. PMID: 7693009

7

Prevalence of hepatitis C virus with different genotypes determined by a group-specific antibody assay in Japanese patients with chronic liver diseases due to hepatitis C virus infection.

Tanaka E, Kiyosawa K, Matsumoto A, Sodeyama T, Urushihara A, Suzuki T, Kobayashi M, Furuta S. Tanaka E, et al. Jpn J Med Sci Biol. 1994 Feb;47(1):47-57. doi: 10.7883/yoken1952.47.47. Jpn J Med Sci Biol. 1994. PMID: 7967159

8

Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C.

Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K. Matsumoto A, et al. Among authors: tanaka e. Dig Dis Sci. 1994 Jun;39(6):1273-80. doi: 10.1007/BF02093793. Dig Dis Sci. 1994. PMID: 8200260 Clinical Trial.

9

Anti-c100 antibodies to hepatitis C virus in patients with chronic hepatitis C virus infection treated with interferon.

Nakano Y, Kiyosawa K, Sodeyama T, Tanaka E, Yoshizawa K, Furuta K, Nakatsuji Y, Urushihara A, Furuta S. Nakano Y, et al. Among authors: tanaka e. Scand J Gastroenterol. 1993 Apr;28(4):335-42. doi: 10.3109/00365529309090252. Scand J Gastroenterol. 1993. PMID: 8387696

10

The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses.

Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. Kobayashi M, et al. Among authors: tanaka e. Hepatology. 1996 Apr;23(4):695-9. doi: 10.1053/jhep.1996.v23.pm0008666319. Hepatology. 1996. PMID: 8666319

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,380 results

Search Page

Filters